Organon & Co. (OGN)
Price:
9.43 USD
( + 0.15 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Bristol-Myers Squibb Company
VALUE SCORE:
6
2nd position
Johnson & Johnson
VALUE SCORE:
10
The best
Merck & Co., Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
NEWS
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation
prnewswire.com
2025-08-13 10:15:00SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Organon & Co. (NYSE: OGN). Investors who purchased shares of Organon & Co. (NYSE: OGN) prior to October 2024 and continue to hold any of those NYSE: OGN shares, also have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Organon: Valuation Discount Offset By Structural Headwinds
seekingalpha.com
2025-08-12 14:22:48Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines; cost-cutting helps margins, but can't reverse the downward trend in earnings. Valuation discounts already reflect worst-case scenarios; fair value is around $9 per share, leaving little upside unless growth drivers emerge.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
zacks.com
2025-08-12 10:01:11Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
OGN vs. HQY: Which Stock Is the Better Value Option?
zacks.com
2025-08-08 12:41:23Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)
seekingalpha.com
2025-08-06 11:59:47Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new products like Emgality and VTAMA are not offsetting losses from older drugs. Women's Health and Biosimilars show some growth, but not enough to reverse the overall negative trend or justify optimism.
Organon (OGN) Fiscal Q2 Revenue Beats 1%
fool.com
2025-08-06 02:47:14Organon (OGN) Fiscal Q2 Revenue Beats 1%
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-05 13:10:49Organon & Co. (NYSE:OGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of Research & Development and Chief Medical Officer Kevin Ali - CEO & Director Matthew M. Walsh - Executive VP & CFO Conference Call Participants Alexandra Doering von Riesemann - Piper Sandler & Co., Research Division Ethan Harris Brown - JPMorgan Chase & Co, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Terence C.
Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2025-08-05 12:01:07The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Organon (OGN) Beats Q2 Earnings and Revenue Estimates
zacks.com
2025-08-05 09:46:04Organon (OGN) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.12 per share a year ago.
Organon Reports Results for the Second Quarter Ended June 30, 2025
businesswire.com
2025-08-05 07:30:00JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon shares results for second quarter ended June 30, 2025.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
zacks.com
2025-08-04 09:51:19The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Insights Into Organon (OGN) Q2: Wall Street Projections for Key Metrics
zacks.com
2025-08-01 10:16:08Get a deeper insight into the potential performance of Organon (OGN) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Organon (OGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
zacks.com
2025-07-31 18:50:45In the most recent trading session, Organon (OGN) closed at $9.7, indicating a -3.39% shift from the previous trading day.
Organon (OGN) Expected to Beat Earnings Estimates: Should You Buy?
zacks.com
2025-07-29 11:06:16Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon (OGN) Outperforms Broader Market: What You Need to Know
zacks.com
2025-07-25 18:51:14In the latest trading session, Organon (OGN) closed at $10.21, marking a +1.39% move from the previous day.
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
zacks.com
2025-07-23 10:01:39Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation
prnewswire.com
2025-08-13 10:15:00SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Organon & Co. (NYSE: OGN). Investors who purchased shares of Organon & Co. (NYSE: OGN) prior to October 2024 and continue to hold any of those NYSE: OGN shares, also have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Organon: Valuation Discount Offset By Structural Headwinds
seekingalpha.com
2025-08-12 14:22:48Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines; cost-cutting helps margins, but can't reverse the downward trend in earnings. Valuation discounts already reflect worst-case scenarios; fair value is around $9 per share, leaving little upside unless growth drivers emerge.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
zacks.com
2025-08-12 10:01:11Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
OGN vs. HQY: Which Stock Is the Better Value Option?
zacks.com
2025-08-08 12:41:23Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)
seekingalpha.com
2025-08-06 11:59:47Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new products like Emgality and VTAMA are not offsetting losses from older drugs. Women's Health and Biosimilars show some growth, but not enough to reverse the overall negative trend or justify optimism.
Organon (OGN) Fiscal Q2 Revenue Beats 1%
fool.com
2025-08-06 02:47:14Organon (OGN) Fiscal Q2 Revenue Beats 1%
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-05 13:10:49Organon & Co. (NYSE:OGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of Research & Development and Chief Medical Officer Kevin Ali - CEO & Director Matthew M. Walsh - Executive VP & CFO Conference Call Participants Alexandra Doering von Riesemann - Piper Sandler & Co., Research Division Ethan Harris Brown - JPMorgan Chase & Co, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Terence C.
Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2025-08-05 12:01:07The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Organon (OGN) Beats Q2 Earnings and Revenue Estimates
zacks.com
2025-08-05 09:46:04Organon (OGN) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.12 per share a year ago.
Organon Reports Results for the Second Quarter Ended June 30, 2025
businesswire.com
2025-08-05 07:30:00JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon shares results for second quarter ended June 30, 2025.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
zacks.com
2025-08-04 09:51:19The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Insights Into Organon (OGN) Q2: Wall Street Projections for Key Metrics
zacks.com
2025-08-01 10:16:08Get a deeper insight into the potential performance of Organon (OGN) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Organon (OGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
zacks.com
2025-07-31 18:50:45In the most recent trading session, Organon (OGN) closed at $9.7, indicating a -3.39% shift from the previous trading day.
Organon (OGN) Expected to Beat Earnings Estimates: Should You Buy?
zacks.com
2025-07-29 11:06:16Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon (OGN) Outperforms Broader Market: What You Need to Know
zacks.com
2025-07-25 18:51:14In the latest trading session, Organon (OGN) closed at $10.21, marking a +1.39% move from the previous day.
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
zacks.com
2025-07-23 10:01:39Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.